Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
Top Page
Shanghai Henlius Biotech, Inc. Class H
(2696)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$64.00
▼(-16.45% Downside)
Action:ReiteratedDate:11/28/25
Shanghai Henlius Biotech's overall stock score is driven by strong financial performance, with significant revenue and profit growth. However, technical indicators suggest potential bearish trends, and the high P/E ratio indicates overvaluation risks. The absence of earnings call insights and corporate events limits further analysis.
Positive Factors
Profitability & Margins
Henlius has converted past losses into sustained profitability with a 73.1% gross margin and a 14.3% net margin in 2024. Durable high margins indicate strong pricing power and product mix, supporting ongoing R&D funding and commercialization without eroding unit economics.
Negative Factors
Higher Leverage
A D/E of 1.21 and declining equity ratio indicate meaningful reliance on debt financing. Persistently higher leverage can constrain strategic flexibility, increase interest expense sensitivity, and limit ability to finance large R&D or commercialization investments without raising additional capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability & Margins
Henlius has converted past losses into sustained profitability with a 73.1% gross margin and a 14.3% net margin in 2024. Durable high margins indicate strong pricing power and product mix, supporting ongoing R&D funding and commercialization without eroding unit economics.
Read all positive factors
Shanghai Henlius Biotech, Inc. Class H (2696) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$27.73B
Dividend YieldN/A
Average Volume (3M)1.53M
Price to Earnings (P/E)34.6
Beta (1Y)0.29
Revenue Growth2.57%
EPS Growth18.79%
CountryHK
Employees3,515
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding346,074,400
10 Day Avg. Volume1,665,497
30 Day Avg. Volume1,532,406
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)4.01
Price to Sales (P/S)2.11
P/FCF Ratio29.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$95.14Price Target Upside24.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shanghai Henlius Biotech, Inc. Class H Business Overview & Revenue Model
Company Description
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treat...
How the Company Makes Money
Shanghai Henlius Biotech generates revenue primarily through the sale of its monoclonal antibody products, which are marketed for various therapeutic indications. The company has established a diversified revenue model that includes direct sales o...
Shanghai Henlius Biotech, Inc. Class H Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
75
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.80B | 5.72B | 5.39B | 3.21B | 1.68B | 587.59M |
| Gross Profit | 4.39B | 4.18B | 3.92B | 2.37B | 1.16B | 405.47M |
| EBITDA | 1.14B | 1.15B | 911.33M | -310.61M | -671.74M | -814.06M |
| Net Income | 824.30M | 820.47M | 546.02M | -695.26M | -984.05M | -993.54M |
Balance Sheet | ||||||
| Total Assets | 11.55B | 10.60B | 9.90B | 8.92B | 7.17B | 6.44B |
| Cash, Cash Equivalents and Short-Term Investments | 972.50M | 772.96M | 1.01B | 680.48M | 742.32M | 1.11B |
| Total Debt | 3.67B | 3.65B | 4.09B | 3.68B | 2.62B | 1.83B |
| Total Liabilities | 8.14B | 7.58B | 7.71B | 7.29B | 4.88B | 3.24B |
| Stockholders Equity | 3.41B | 3.01B | 2.19B | 1.64B | 2.30B | 3.20B |
Cash Flow | ||||||
| Free Cash Flow | 930.30M | 404.68M | 36.48M | -383.67M | -1.04B | -2.12B |
| Operating Cash Flow | 990.62M | 1.24B | 1.05B | 981.62M | 90.39M | -609.58M |
| Investing Cash Flow | -123.16M | -909.97M | -1.00B | -1.36B | -1.68B | -1.51B |
| Financing Cash Flow | 0.00 | -643.37M | 144.43M | 858.02M | 648.30M | 995.79M |
Shanghai Henlius Biotech, Inc. Class H Technical Analysis
Positive
76.60
Price Trends
65.81
Positive
65.05
Positive
67.12
Positive
Market Momentum
1.82
Negative
67.15
Neutral
86.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2696, the sentiment is Positive. The current price of 76.6 is above the 20-day moving average (MA) of 68.31, above the 50-day MA of 65.81, and above the 200-day MA of 67.12, indicating a bullish trend. The MACD of 1.82 indicates Negative momentum. The RSI at 67.15 is Neutral, neither overbought nor oversold. The STOCH value of 86.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2696.
Shanghai Henlius Biotech, Inc. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$23.20B | 31.11 | -3.42% | ― | 58.24% | 38.85% | |
66 Neutral | HK$27.73B | 34.57 | 25.67% | ― | 2.57% | 18.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.58B | -22.62 | -14.53% | ― | 38.56% | 48.26% | |
45 Neutral | HK$17.86B | -10.93 | -22.81% | ― | 23.87% | 30.08% | |
44 Neutral | HK$19.28B | -6.78 | -123.74% | ― | -56.94% | -190.36% |
* Healthcare Sector Average
HK:2696
Shanghai Henlius Biotech, Inc. Class H
76.60
50.50
193.49%
HK:9688
Zai Lab Ltd
15.78
-7.27
-31.54%
HK:9969
InnoCare Pharma Ltd.
15.52
7.84
102.08%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.38
13.18
99.85%
HK:2096
Simcere Pharmaceutical Group Limited
13.62
6.17
82.82%
HK:6855
Ascentage Pharma Group International
52.05
17.40
50.22%
Shanghai Henlius Biotech, Inc. Class H Corporate Events
Shanghai Henlius Completes Full Circulation of H Shares on Hong Kong Stock Exchange
Feb 4, 2026
Shanghai Henlius Biotech has completed the conversion of 182,645,856 previously unlisted shares into H shares, marking the full circulation of its H shares on the Hong Kong Stock Exchange. Following the conversion, the company’s share struct...
Henlius Wins NMPA Nod for Triple-Drug Cancer Combination Trial Centered on HLX43
Jan 27, 2026
Shanghai Henlius Biotech, Inc. announced that China’s National Medical Products Administration has approved its application to conduct a clinical trial of HLX43, an anti-PD-L1 antibody-drug conjugate, in combination with HLX07, an anti-EGFR ...
Henlius Wins NMPA Nod to Trial Novel CD47-Targeting Fusion Protein in Advanced Colorectal Cancer
Jan 20, 2026
Shanghai Henlius Biotech has received approval from China’s National Medical Products Administration for an investigational new drug application to conduct a phase 1b/2 clinical trial of HLX701, a recombinant human SIRPα–IgG4 Fc f...
Henlius Wins HKEX Approval for Full Circulation of 182.6 Million H Shares
Jan 19, 2026
Shanghai Henlius Biotech, Inc. has received approval from the Stock Exchange of Hong Kong for the listing and trading of 182,645,856 converted H shares, enabling full circulation of these previously unlisted shares. The conversion involves 17 part...
Henlius Biotech Cleared by CSRC to Proceed With H Share Full Circulation
Jan 16, 2026
Shanghai Henlius Biotech has received a filing notice from the China Securities Regulatory Commission confirming completion of the regulatory filing for its H share full circulation plan, covering 182,645,856 previously unlisted domestic shares he...
Henlius Wins FDA Acceptance of BLA for Bevacizumab Biosimilar HANBEITAI
Jan 13, 2026
Shanghai Henlius Biotech has announced that the US Food and Drug Administration has accepted its biologics license application for HANBEITAI, a bevacizumab injection developed in-house, for use across six cancer indications including metastatic co...
Henlius Renews Key Fosun-Linked Leasing, Financial and Promotion Deals
Dec 31, 2025
Shanghai Henlius Biotech has renewed its property leasing framework agreements with Clone High Tech and Fukun Pharmaceutical, both subsidiaries of controlling shareholder Fosun Pharma, extending the lease of certain premises for three years from 1...
Henlius Shareholders Approve Renewal of Sinopharm Distribution Framework Agreement
Dec 31, 2025
Shanghai Henlius Biotech, Inc. announced that shareholders approved an ordinary resolution at its fourth extraordinary general meeting of 2025, held in Shanghai on 31 December, with all directors in attendance and 16.38% of share capital represent...
Shanghai Henlius Doses First Patient in Phase 1 Trial of PD-L1/VEGF Bispecific HLX37
Dec 29, 2025
Shanghai Henlius Biotech has initiated a first-in-human phase 1 clinical trial in mainland China for HLX37, a recombinant humanised bispecific antibody that simultaneously targets PD-L1 and VEGF, in patients with advanced or metastatic solid tumou...
Henlius Wins FDA Clearance to Start US Trial of Nivolumab Biosimilar HLX18
Dec 19, 2025
Shanghai Henlius Biotech has received approval from the U.S. Food and Drug Administration for its investigational new drug application to begin a phase 1 clinical trial in the United States of HLX18, a nivolumab biosimilar designed as a recombinan...
Shanghai Henlius Biotech’s Gastric Cancer Treatment Gains Priority Review in China
Dec 12, 2025
Shanghai Henlius Biotech, Inc. announced that its New Drug Application for HANSIZHUANG, a serplulimab injection used in combination with chemotherapy for gastric cancer treatment, has been accepted by the National Medical Products Administration i...
Shanghai Henlius Biotech Advances Cancer Treatment Trials
Dec 9, 2025
Shanghai Henlius Biotech, Inc. announced the approval of phase 2/3 clinical trials for its HLX22 and HLX87 combination therapy for HER2-positive breast cancer by the National Medical Products Administration. This development signifies a significan...
Shanghai Henlius Biotech’s FUTUONING Added to National Drug List
Dec 7, 2025
Shanghai Henlius Biotech, Inc. announced that its product, FUTUONING (Fovinaciclib Citrate Capsules), has been included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance for...
Shanghai Henlius Biotech Expands Breast Cancer Portfolio Through Avanc Pharma Collaboration
Dec 3, 2025
Shanghai Henlius Biotech, Inc. has entered into collaboration agreements with Avanc Pharma to commercialize Fovinaciclib Citrate Capsules, a CDK4/6 inhibitor for HR+ and HER2-breast cancer, in China. This collaboration aligns with Henlius’s ...
Shanghai Henlius Biotech Renews Sinopharm Distribution Agreement
Dec 3, 2025
Shanghai Henlius Biotech, Inc. has renewed its distribution collaboration with Sinopharm, extending the agreement until December 2028. This renewal, subject to Hong Kong Listing Rules, positions Sinopharm as a key distributor of Henlius’s pr...
Shanghai Henlius Biotech to Hold EGM for Sinopharm Agreement Approval
Dec 3, 2025
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting scheduled for December 31, 2025, to consider the approval of the Sinopharm Distribution Framework Agreement (2025 Renewal). This agreement, if approved, will facilitate ...
Shanghai Henlius Biotech’s HLX14 Biosimilar Gains NMPA Acceptance
Dec 2, 2025
Shanghai Henlius Biotech, Inc. announced that its New Drug Application for HLX14, a biosimilar of denosumab, has been accepted by the National Medical Products Administration in China. This development marks a significant step for the company as H...
Shanghai Henlius Biotech’s HLX37 Receives IND Approval for Phase 1 Trials
Dec 1, 2025
Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX37, a recombinant humanised bispecific antibody targeting PD-L1 and VEGF, has been approved by the National Medical Products Administration for phase 1 c...
Shanghai Henlius Initiates Phase 1 Study of HLX13 for Liver Cancer
Nov 25, 2025
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in an international multicenter phase 1 clinical study of its Ipilimumab biosimilar, HLX13, for treating unresectable hepatocellular carcinoma (HCC) in mainland China. Th...
Shanghai Henlius Biotech’s HANSIZHUANG Receives Breakthrough Therapy Designation
Nov 20, 2025
Shanghai Henlius Biotech, Inc. announced that its HANSIZHUANG (serplulimab injection), in combination with chemotherapy, has received Breakthrough Therapy Designation from China’s National Medical Products Administration for the treatment of...
Shanghai Henlius Biotech’s HLX11 Receives FDA Approval for Breast Cancer Treatment
Nov 14, 2025
Shanghai Henlius Biotech, Inc. has announced that its biosimilar product, HLX11 (pertuzumab-dpzb), branded as POHERDY® in the United States, has received FDA approval for use in treating HER2-positive early and metastatic breast cancer. This ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.